166 related articles for article (PubMed ID: 8721904)
1. Correlation between steady-state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters.
Woo J; Chan C; Chan R; Cheung W; Or K; Chan K
J Med; 1995; 26(5-6):279-94. PubMed ID: 8721904
[TBL] [Abstract][Full Text] [Related]
2. The disposition of antituberculous drugs in plasma of elderly patients. I. Isoniazid and hydrazine metabolite.
Walubo A; Chan K; Woo J; Chan HS; Wong CL
Methods Find Exp Clin Pharmacol; 1991 Oct; 13(8):545-50. PubMed ID: 1956209
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions and outcome of elderly patients on antituberculosis chemotherapy with and without rifampicin.
Chan CH; Or KK; Cheung W; Woo J
J Med; 1995; 26(1-2):43-52. PubMed ID: 7561530
[TBL] [Abstract][Full Text] [Related]
4. The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide.
Walubo A; Chan K; Woo J; Chan HS; Wong CL
Methods Find Exp Clin Pharmacol; 1991 Oct; 13(8):551-6. PubMed ID: 1956210
[TBL] [Abstract][Full Text] [Related]
5. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic problems in the management of elderly patients with tuberculosis.
Woo J; Chan HS
Adverse Drug React Toxicol Rev; 1992; 11(1):13-8. PubMed ID: 1606279
[TBL] [Abstract][Full Text] [Related]
7. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
8. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
10. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
Cohen K; van Cutsem G; Boulle A; McIlleron H; Goemaere E; Smith PJ; Maartens G
J Antimicrob Chemother; 2008 Feb; 61(2):389-93. PubMed ID: 18096560
[TBL] [Abstract][Full Text] [Related]
11. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon.
Kuaban C; Bercion R; Koulla-Shiro S
East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410
[TBL] [Abstract][Full Text] [Related]
12. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
13. [Adverse effects related to the use of antitubercular drugs in psychiatric centers: retrospective study at the Philippe Pinel CH in Amiens 1994].
Decocq G; Compagnon M; Andréjak M; Guedj B; Doutrellot C
Therapie; 1996; 51(5):543-9. PubMed ID: 9138390
[TBL] [Abstract][Full Text] [Related]
14. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
[TBL] [Abstract][Full Text] [Related]
15. [Desensitization therapy for allergic reactions of antituberculous drugs--evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis].
Kobashi Y; Okimoto N; Matsushima T; Abe T; Nishimura K; Shishido S; Kawahara S; Shigeto E; Takeyama H; Kuraoka T
Kekkaku; 2000 Dec; 75(12):699-704. PubMed ID: 11201137
[TBL] [Abstract][Full Text] [Related]
16. Hydrazine--a possible cause of isoniazid--induced hepatic necrosis.
Woo J; Chan CH; Walubo A; Chan KK
J Med; 1992; 23(1):51-9. PubMed ID: 1573341
[TBL] [Abstract][Full Text] [Related]
17. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
[TBL] [Abstract][Full Text] [Related]
18. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin].
Pilheu JA; Galati MR; Yunis AS; De Salvo MC; Negroni R; García Fernández JC; Mingolla L; Rubio MC; Masana M; Acevedo C
Medicina (B Aires); 1989; 49(1):43-7. PubMed ID: 2698437
[TBL] [Abstract][Full Text] [Related]
20. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
